Prolactin Determinants in Healthy Women: A Large Cross-Sectional Study within the EPIC Cohort

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: onr:"swepub:oai:DiVA.org:umu-97593" > Prolactin Determina...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04963naa a2200781 4500
001		oai:DiVA.org:umu-97593
003		SwePub
008		141223s2014 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:130135327
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-975932 URI
024	7	a https://doi.org/10.1158/1055-9965.EPI-14-06132 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1301353272 URI
040		a (SwePub)umud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Tikk, Kaja4 aut
245	1 0	a Prolactin Determinants in Healthy Women :b A Large Cross-Sectional Study within the EPIC Cohort
264	1	c 2014
338		a print2 rdacarrier
520		a Background: Experimental and epidemiologic data suggest that higher circulating prolactin is associated with breast cancer risk; however, how various risk factors for breast cancer influence prolactin levels in healthy women is not clear. Methods: We analyzed cross-sectional associations between several suggested reproductive and lifestyle risk factors for breast cancer and circulating prolactin among pre- and postmenopausal women, taking into account the use of current postmenopausal hormone therapy, among 2,560 controls from a breast cancer nested case-control study within the EPIC cohort. Results: Adjusted geometric mean prolactin levels were significantly higher among premenopausal women, and among postmenopausal women using hormone therapy compared with nonusers (8.2, 7.0, and 6.3 ng/mL, respectively; P-cat = <0.0001). Furthermore, prolactin levels were significantly higher among users of combined estrogen-progestin hormone therapy compared with users of estrogen-alone hormone therapy (6.66 vs. 5.90 ng/mL; P-cat = 0.001). Prolactin levels were lower among parous women compared with nulliparous women (8.61 vs. 10.95 ng/mL; P-cat = 0.0002, premenopausal women); the magnitude of this difference depended on the number of full-term pregnancies (22.1% lower, >= 3 vs. 1 pregnancy, P-trend = 0.01). Results for parity were similar but lower in magnitude among postmenopausal women. Prolactin did not vary by other studied factors, with the exception of lower levels among postmenopausal smokers compared with never smokers. Conclusions: Our study shows that current hormone therapy use, especially the use of combined hormone therapy, is associated with higher circulating prolactin levels in postmenopausal women, and confirms prior findings of lower circulating prolactin in parous women. Impact: Our study extends the knowledge linking various breast cancer risk factors with circulating prolactin.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700	1	a Sookthai, Disorn4 aut
700	1	a Johnson, Theron4 aut
700	1	a Dossus, Laure4 aut
700	1	a Clavel-Chapelon, Francoise4 aut
700	1	a Tjonneland, Anne4 aut
700	1	a Olsen, Anja4 aut
700	1	a Overvad, Kim4 aut
700	1	a Baglietto, Laura4 aut
700	1	a Rinaldi, Sabina4 aut
700	1	a Romieu, Isabelle4 aut
700	1	a Boeing, Heiner4 aut
700	1	a Trichopoulou, Antonia4 aut
700	1	a Lagiou, Pagona4 aut
700	1	a Trichopoulos, Dimitrios4 aut
700	1	a Masala, Giovanna4 aut
700	1	a Agnoli, Claudia4 aut
700	1	a Tumino, Rosario4 aut
700	1	a Sacerdote, Carlotta4 aut
700	1	a Mattiello, Amalia4 aut
700	1	a Buckland, Genevieve4 aut
700	1	a Sanchez, Soledad4 aut
700	1	a Molina-Montes, Esther4 aut
700	1	a Amiano, Pilar4 aut
700	1	a Huerta Castano, Jose Maria4 aut
700	1	a Barricarte, Aurelio4 aut
700	1	a Bueno-de-Mesquita, H. Bas4 aut
700	1	a Monninkhof, Evelyn M.4 aut
700	1	a Onland-Moret, N. Charlotte4 aut
700	1	a Idahl, Annikau Umeå universitet,Obstetrik och gynekologi4 aut0 (Swepub:umu)anid0002
700	1	a Lundin, Evau Umeå universitet,Patologi4 aut0 (Swepub:umu)evlu0001
700	1	a Weider-pass, Elisabete4 aut
700	1	a Lund, Eiliv4 aut
700	1	a Waaseth, Marit4 aut
700	1	a Khaw, Kay-Tee4 aut
700	1	a Key, Timothy J.4 aut
700	1	a Travis, Ruth C.4 aut
700	1	a Gunter, Marc J.4 aut
700	1	a Riboli, Elio4 aut
700	1	a Kaaks, Rudolf4 aut
710	2	a Umeå universitetb Obstetrik och gynekologi4 org
773	0	t Cancer Epidemiology, Biomarkers and Preventiong 23:11, s. 2532-2542q 23:11<2532-2542x 1055-9965x 1538-7755
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-97593
856	4 8	u https://doi.org/10.1158/1055-9965.EPI-14-0613
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:130135327

Hitta via bibliotek

Cancer Epidemiology, Biomarkers and Prevention (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Cancer Epidemiol ...

Av lärosätet: Umeå universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se